Drug intelligence / Profile preview

Ocular CBD

Development stage
Preclinical
Lead developer
BioNanoSim
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Ophthalmic
01

Overview

Ocular CBD is a cannabidiol-based formulation developed by BioNanoSim for the treatment of various ocular conditions. The product leverages BioNanoSim's proprietary nanotechnology-based delivery platform (BNS technology) to enhance the solubility and bioavailability of cannabidiol (CBD), a lipophilic cannabinoid, for effective delivery to ocular tissues. CBD is a non-psychoactive cannabinoid known to interact with the endocannabinoid system and other molecular targets, including cannabinoid receptors (CB1 and CB2), TRPV1, and GPR55, to exert anti-inflammatory, antioxidant, and neuroprotective effects. Although categorized under BioNanoSim's "Non-Pharma Track," the formulation is intended for ophthalmic application to address ocular pathologies where modulation of these pathways may provide therapeutic benefit.

Other names
cannabidiolCBD
02

Targets

CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on Ocular CBD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocular CBD.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call